NVAX

Biogen shares surged 5.3% to $253.84 driven by positive phase II data from its AMETHYST study for litifilimab in cutaneous lupus erythematosus, with phase III data expected in H1 2027. However, the company's consensus EPS estimate was revised 1.8% lower over the past month, which could limit further price appreciation. Novavax declined 9.3% to $9.99 with its EPS estimate revised down 8.1% over the past month.

Novavax (NVAX) has been heavily searched by investors recently, outperforming the S&P 500 by 4.8% over the past month. However, the company faces significant headwinds with revenue declining 66.4% for the current fiscal year and 9.5% for the next year. While the company has beaten earnings and revenue estimates in the trailing four quarters, it carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Novavax stock declined 3.91% to $10.82, underperforming the broader market's gains. While the vaccine maker gained 11.38% over the past month, upcoming earnings expectations show challenges ahead with anticipated EPS of -$0.33 and revenue declining 28.15% year-over-year. The company holds a Zacks Rank #3 (Hold) rating.

Novavax stock closed at $12.82, up 1.26% and outperforming the broader market decline. The vaccine maker has surged 32.01% over the past month.

However, upcoming earnings show mixed signals: EPS expected to improve 46.77% YoY to -$0.33, but revenue projected to fall 28.15% to $50.61 million. Full-year estimates show significant declines with -114.73% EPS change and -66.4% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating.

Novavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Novavax (NVAX) closed down 10.31% in recent trading. The vaccine maker faces headwinds with projected quarterly EPS of -$0.37 and revenue expected to decline 39.01% year-over-year to $42.96 million.

Full-year estimates show -$0.46 EPS and $357.88 million revenue, representing significant declines. The stock holds a Zacks Rank #4 (Sell) rating with no recent changes to consensus estimates.

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.

Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.